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Introduction: Over the last 40 years omega-3 polyunsaturated fatty acids (PUFAs) have
been shown to be anti-arrhythmic or pro-arrhythmic depending on the method and
duration of administration and model studied. We previously reported that omega-3
PUFAs do not confer anti-arrhythmic properties and are pro-arrhythmic in canine model
of sudden cardiac death (SCD). Here, we evaluated the effects of chronic omega-3
PUFA treatment in post-MI animals susceptible (VF+) or resistant (VF−) to ventricular
tachyarrhythmias.
Methods: Perforated patch clamp techniques were used to measure cardiomyocyte
action potential durations (APD) at 50 and 90% repolarization and short term variability
of repolarization. The early repolarizing transient outward potassium current Ito was also
studied.
Results: Omega-3 PUFAs prolonged the action potential in VF− myocytes at both 50
and 90% repolarization. Short term variability of repolarization was increased in both
untreated and treated VF− myocytes vs. controls. Ito was unaffected by omega-3 PUFA
treatment. Omega-3 PUFA treatment attenuated the action potential prolongation in VF+
myocytes, but did not return repolarization to control values.
Conclusions: Omega-3 PUFAs do not confer anti-arrhythmic properties in the setting
of healed myocardial infarction in a canine model of SCD. In canines previously resistant
to ventricular fibrillation (VF−), omega-3 PUFA treatment prolonged the action potential
in VF− myocytes, and may contribute to pro-arrhythmic responses.
Keywords: omega-3 polyunsaturated fatty acids, ventricular fibrillation, electrophysiology, potassium current,
myocardial infarction
INTRODUCTION
Sudden cardiac death (SCD) caused by ventricular tachy-arrhythmias is the leading cause of
death in the United States and contributes to 15–20% of deaths worldwide (Hayashi et al., 2015).
Myocardial infarction and resulting scar tissue result in structural and electrical remodeling leading
to an arrhythmogenic substrate; at the cellular level repolarization abnormalities and calcium
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dysregulation occur which can contribute to ventricular
tachyarrhythmia formation and SCD (Rubart and Zipes, 2005;
Wagner et al., 2015). Treatments that normalize repolarization
may be anti-arrhythmic in the setting of healed MI and decrease
the susceptibility to SCD (Billman, 2006).
The effects of omega-3 polyunsaturated fatty acid (PUFA)
consumption and cardiovascular health have been studied for
more than 40 years (Dyerberg et al., 1978). While observational
studies suggest a role for omega-3 PUFAs in preventing cardiac
mortality(Kromhout et al., 1985), results from studies using
omega-3 PUFAs as secondary prevention of cardiovascular
events have shown mixed results (Gillum et al., 1996; Erkkila
et al., 2003; Wilhelm et al., 2008; Smith et al., 2009). Despite
mixed results of prior studies the American Heart Association
recommends eating fatty fish containing the active ingredients
docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA)
two times per week in patients with or without existing coronary
heart disease (CHD) and 1 g of EPA+DHA by capsule per day in
patients with existing CHD (Gebauer et al., 2006).
Cellular experiments have demonstrated that acute
administration of omega-3 PUFAs are able to modulate a
number ion currents including calcium, sodium, and potassium
currents (Dhein et al., 2005; Guizy et al., 2005; Meves, 2008).
However, it is not clear if these effects are pro-arrhythmic
or anti-arrhythmic (Belevych et al., 2013). We previously
reported that acute administration of omega-3 PUFAs through
intravenous infusion of a fish oil emulsion prevented ventricular
fibrillation in canines susceptible to induction of ventricular
fibrillation (VF+) in a clinically relevant model of SCD (Leaf
et al., 2003). In contrast, dietary administration of omega-3
PUFAs did not confer protection against VF (Billman et al.,
2012). Furthermore, omega-3 PUFAs were shown to be pro-
arrhythmic and cause SCD in the same animal model (Billman
et al., 2012). Additionally, Coronel et al. reported that chronic
dietary administration of omega-3 PUFAs were pro-arrhythmic
and shortened the action potential in a regionally ischemic
porcine model (Coronel et al., 2007).
The purpose of the current study was to elucidate the cellular
electrophysiological effects caused by chronic dietary omega-3
PUFAs supplementation in a post-MI canine model of sudden
death at both high (VF+) and low (VF−) risk of developing
ventricular arrhythmias.
MATERIALS AND METHODS
All animal procedures were approved by The Ohio State
University Institutional Animal Care and Use committee and
conformed to the Guide for the Care and Use of Laboratory
Animals published by the US National Institute of Health (NIH
publication No. 85-23, revised 1996). Forty-three heartworm free
mixed breed dogs had a left ventricular anterior myocardial
infarction induced as previously described (Billman, 2006).
Seventeen healthy age-matched dogs served as controls.
In vivo Preparation
The animal model, omega-3 PUFA treatment protocol, and in
vivo assessments have been previously described (Sridhar et al.,
2008; Billman et al., 2012). Briefly, the left anterior descending
coronary artery was occluded to induce a left anterior myocardial
infarction (Billman et al., 1982; Billman, 2006). After recovery (3–
4 weeks) the susceptibility to ventricular fibrillation was tested
using a standardized exercise plus ischemia test (Billman, 2006;
Babu et al., 2007; Sridhar et al., 2008). The exercise plus ischemia
test reliably induced ventricular flutter/fibrillation in animals
which were then classified as VF+. Those without induced
sustained ventricular tachy-arrhythmias were classified as VF−
(Sridhar et al., 2008).
Omega-3 PUFA Protocol
To prevent confounding dietary omega-3 PUFA intake, dogs
used for the omega-3 PUFA experiments were fed a diet free
of omega-3 PUFAs (Harland Teklad, Harlan Laboratories, Inc.,
Indianapolis, IN, USA) for the duration of the study (∼4
months; Billman et al., 2010, 2012). Dogs were randomly assigned
to the following groups: untreated VF+ n = 11, untreated
VF− n = 8, treated VF+ n = 11, and treated VF− n = 13
(Figure 1). Dogs in the treated group received 465mg ethyl
eicosapentaenoate, EPA+ ethyl docosahexaenoate, DHA, 375mg
per 1 g capsule (Lovaza R©, GlaxoSmithKline, Research Triangle
FIGURE 1 | Study design and treatment groups. Three to four weeks after
myocardial infarction, dogs were classified as susceptible or resistant to
ventricular fibrillation (VF) with an exercise plus ischemia test. Three month
treatment was randomly assigned, and the exercise plus ischemia test was
repeated at the end of treatment. N, number of animals; LAD, Left anterior
descending artery; MI, myocardial infarction.
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Park, NC); doses of 1, 2, and 4 g where administered. The
capsules were given orally prior to the daily feeding (7 days
per week for 3 months) as previously reported (Billman et al.,
2012). The exercise plus ischemia test was repeated after the
omega-3 PUFA treatment period (Billman et al., 2012). Since
no dose-dependent differences in response were found in this
or previous work in this model (Billman et al., 2010), results
from all dose groups were combined. Omega-3 PUFA treatment
induced malignant arrhythmias in ∼33% of the VF− dogs,
indicating a pro-arrhythmic effect of treatment (Billman et al.,
2012). In the VF+ dogs, omega-3 PUFA treatment did not confer
any protection against malignant arrhythmias, as we previously
reported (Billman et al., 2012). Since no significant cellular
electrophysiological differences based on treatment response
were found in either the VF− dogs or the VF+ dogs, canines were
grouped as omega-3 PUFA treated VF− or VF+, respectively.
Figure 1 provides a detailed schematic of the dog classification.
Myocyte Isolation
Myocytes were isolated as previously described (Sridhar et al.,
2008; Bonilla et al., 2014). Briefly, left ventricular myocytes were
isolated aminimum of 5 days after the final exercise plus ischemia
test to avoid potential residual effects of acute ischemia. Dogs
where anesthetized by intravenous injection of pentobarbital
sodium (dosage: 120 mg/kg for the first 4.5 kg and 60 mg/kg
for every 4.5 thereafter). After a deep plane of anesthesia was
achieved, the heart was rapidly removed and perfused with cold
cardioplegia solution containing the following in mM: NaCl 110,
CaCl2 1.2, KCl 16, MgCl2 16, and NaHCO3 10. Cannulation of
the left circumflex artery was used to perfuse the left ventricle
as previously described (Bonilla et al., 2012). In post-MI dogs a
clear margin of infarct was visible as scar tissue. After enzymatic
digestion of the left ventricle (Bonilla et al., 2012; Belevych et al.,
2013), the digested non-infarctedmidmyocardial section (at least
1 cm from the scar border) was used as the source of myocytes.
This method typically yielded 50–70% rod shaped ventricular
myocytes. The myocytes were stored at room temperature in
a standard incubation buffer containing the following in mM:
118 NaCl, 4.8 KCl, 1.2 MgCl2, 1.2 KH2PO4, 0.68 glutamine, 10
glucose, 5 pyruvate, 1 CaCl2, along with 1 µmol/L insulin, and
1% BSA until use. All myocyte electrophysiological experiments
were conducted within 10 h of myocyte isolation.
Electrophysiological Protocols
To assess myocyte electrophysiology amphotericin-B perforated
patch clamp techniques with a bath temperature of 36 ± 0.5◦C
were used. Myocytes were placed in a laminin coated cell
chamber (Cell Microcontrols, Norfolk, VA) and superfused with
bath solution containing in mM: 135 NaCl, 5 MgCl2, 5 KCl, 10
glucose, 1.8 CaCl2, and 5 HEPES with pH adjusted to 7.40 with
NaOH. Borosilicate glass micropipettes with tip resistance of 1.5–
3 M were filled with pipette solution containing the following
in mM: 100 K-aspartate, 40 KCl, 5 MgCl, 5 EGTA, 5 HEPES, pH
adjusted to 7.2 with KOH.
Action potential duration (APD) measurements were
obtained from the average of the last 10 traces (steady state)
from a train of 25 action potentials elicited at each stimulation
rate. To evaluate beat to beat variability, Poincaré plots of
the last 10 consecutive beats were drawn by plotting each
APD90 (APD90 n + 1) against the APD90 of the previous
beat (APD90 n) as previously reported (Varkevisser et al.,
2012; Belevych et al., 2013). Short term variability of APD90,
expressed in ms, was calculated by using the following formula:∑
(APD90n+ 1− APD90n)/
(
10×
√
2
)
as previously reported
(Varkevisser et al., 2012; Belevych et al., 2013).
For Ito recordings, only recordings with an access resistance
<20 M were included in the analyses. Calcium in the bath
solution was reduced to 1.0 mM and 2 µM nifidepine was added
to block L-type Ca2+ current. Ito was elicited from a holding
potential of −60 mV by a series of 100 ms test potentials from
−30 to+50mV andmeasured as peak current minus steady state
current as previously described (Belevych et al., 2013).
Solutions and Chemicals
All chemicals used for buffer and solution preparation were
purchased from Sigma Aldrich (St. Louis, CS) unless otherwise
noted. Cardioplegia and solutions containing nifidepine and
amphotericin-B were prepared daily.
Interstitial Fibrosis
Transmural right ventricular tissue samples were formalin fixed
and embedded in paraffin and sectioned to 5 µm thickness, using
standard procedures. Tissue sections were stained with Masson’s
Trichrome to define the percentage area of fibrosis, as previously
described (Nishijima et al., 2007).
Data Analysis
Cellular electrophysiology data were analyzed using Clampfit
10.3 software (Axon Instruments) and Origin 9.0 software
(OriginLab, Northampton, MA, USA). Comparisons between
three or more groups were analyzed by one-way ANOVA
with post hoc least significant difference testing (Originpro 8.6,
OriginLab). All data are presented as mean ± SE and p < 0.05
was the criterion for statistical significance for all comparisons.
RESULTS
Omega-3 PUFA Treatment of VF− Canines
Causes a Prolongation of Cellular
Repolarization
APD at 90% repolarization (APD90) in untreated VF− cells was
significantly prolonged compared to control at 0.5 and 2 Hz (p<
0.05); no differences were observed in APD at 50% repolarization
(APD50; Figure 2). However, omega-3 PUFA treatment of VF−
dogs caused a significant prolongation of APD50 at 0.5 and 1 Hz
(p < 0.05 vs. control and untreated VF−) and increased APD90
at all rates compared to untreated VF− (p < 0.05 vs. untreated
VF− and control; Figure 2). Short term variability was measured
to assess the instability of the action potential, a measure of
pro-arrhythmic potential. Both untreated VF− and the omega-
3 PUFA treated VF− groups had increased short term variability
vs. control (p < 0.05), while omega-3 PUFA treatment did not
affect short term variability (Figure 2).
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FIGURE 2 | Omega-3 PUFA treatment prolongs repolarization in VF−myocytes. (A) Representative tracings of action potentials of control, untreated VF−, and
omega-3 PUFA treated VF− cardiomyocytes. (B) APD50 is significantly increased in the omega-3 PUFA treated VF− myocytes compared to both control and
untreated VF− cardiomyocytes (P < 0.05 vs. control and untreated VF− 0.5 and 1 Hz). (C) APD90 is significantly increased in the omega-3 PUFA treated group at all
rates; compared to both control and untreated VF− cardiomyocytes (P < 0.05 vs. control and untreated VF− at 0.5, 1, and 2 Hz). (D) Short term variability of APD90
is not further increased by omega-3 PUFA treatment (P < 0.05 vs. control at all rates). Insert: Representative Poincaré Plot of APD90 from control, Untreated VF− and
O-3 VF− groups, 6–8 animals per group, n = number of cells.
Cardiac Transient Outward Potassium
Current (Ito) Is Unaffected by Omega-3
PUFA Treatment in VF− Animals
In accordance with our previous study, Ito current was
significantly reduced in the untreated VF− group compared to
control (p < 0.05 vs. control). Omega-3 PUFA treatment had no
effect on Ito current vs. untreated VF− canines (Figure 3).
Omega-3 PUFA Treatment of Animals
Susceptible to Ventricular Arrhythmias
(VF+) Causes a Shortening of the Action
Potential
Previously we found that myocytes from animals susceptible
to ventricular fibrillation (VF+) had a significantly prolonged
APD50 and APD90 compared to controls (Sridhar et al., 2008).
Omega-3 PUFA treatment caused a significant shortening of
the APD50 (1 Hz) and APD90 (0.5 and 1 Hz) compared to
untreated VF+, however, repolarization remained prolonged
vs. control (p < 0.05 vs. control and untreated VF+).
At 2 Hz omega-3 PUFA treatment did not alter APD
(Figure 4).
Short term variability of the APD at 90% of repolarization
(STV) in VF+myocytes was significantly increased compared to
control myocytes at 1 and 2 Hz (P < 0.05 vs. control). Omega-3
PUFA treatment caused a significant reduction of STV at 1 Hz,
yet was increased relative to controls (p < 0.05 vs. control and
untreated VF+, Figure 4).
Cardiac Transient Outward Potassium
Current (Ito) Is Unaffected by Omega-3
PUFA Treatment in VF+ Animals
Consistent with our previous report (Sridhar et al., 2008), Ito was
reduced in myocytes from VF+ canines (p < 0.5 vs. control;
Figure 5). Omega-3 PUFA treatment had no effect on Ito vs.
untreated VF+ canines.
Interstitial Fibrosis
Right ventricular tissue fibrosis was 14.0± 1.1%, and unchanged
by infarction in either the VF− group (10.5 ± 1.2%) or VF+
group (10.8 ± 5.6%). Omega-3 PUFA treatment did not alter
fibrosis in either the VF− or VF+ group (data not shown,
p= NS).
DISCUSSION
In the present study we tested the hypothesis that dietary omega-
3 PUFA supplementation would mediate electrophysiologic
effects evident at the cellular level in the post-infarction setting. A
major finding of this study is that in post-MI animals resistant to
VF, omega-3 PUFA treatment caused a significant prolongation
of the action potential and did not have beneficial effects
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FIGURE 3 | Omega-3 PUFA treatment does not affect Ito in myocytes from VF− animals. (A) I–V curve. (B) Slope conductance. Ito density and slope
conductance is significantly lower in VF− vs. control cardiomyocytes and unaffected by omega-3 PUFA treatment (P < 0.05 vs. control). Three to six animals per
group; n = number of cells.
FIGURE 4 | Omega-3 PUFA treatment attenuates action potential duration prolongation in myocytes from VF+ myocytes. (A) Representative tracings of
action potentials of control, untreated VF+ and omega-3 PUFA treated VF+ cardiomyocytes. (B) APD50 is prolonged in VF+ myocytes at 0.5 and 1 Hz, the
prolongation is attenuated only at 1 Hz (P > 0.05). (C) APD90 is significantly prolonged in the VF+ group; omega-3 PUFA treatment attenuated the prolongation at 0.5
and 1 Hz (P < 0.05). (D) Short term variability of APD90 is decreased only at 1 Hz, but remains significantly higher than in control cardiomyocytes (P < 0.05 vs. control
at 1 Hz). Insert shows a representative Poincaré Plot of APD90 at 1 Hz from control, Untreated VF+ and O-3 VF+ groups. Five to seven animals per group; n =
number of cells.
on repolarization instability, consistent with pro-arrhythmic
potential. Additionally, dietary Omega-3 PUFAs significantly
shortened the action potential of dogs susceptible to VF (VF+)
compared to untreated dogs, but did not consistently improve
repolarization instability. Collectively, while we did observe
cellular electrophysiologic effects of omega-3 PUFA treatment,
these were insufficient to protect against malignant arrhythmias
induced by acute myocardial ischemia in vivo in the VF+
animals.
Epidemiological studies from Bang and Dyerberg suggests
beneficial results from the intake of omega-3 PUFAs, based on
initial observations in a population of Greenland Inuits (Bang
et al., 1971). This led to the hypothesis that increased omega-3
PUFA consumption is inversely correlated with SCD, although
more recent data suggests genetic adaptations to dietary omega-
3 PUFAs may exist in this population, and may contribute to
the observed effects (Fumagalli et al., 2015). Early clinical and
investigational trials confirmed this inverse relationship. For
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FIGURE 5 | Omega-3 PUFA treatment does not affect Ito in VF+ myocytes. (A) I–V curve and (B) Slope conductance of control, untreated VF+, and omega-3
PUFA treated VF+ cardiomyocytes. Ito is reduced in VF+ myocytes and unaffected by omega-3 PUFA treatment (P < 0.05 vs. control). Three to seven animals per
group; n = number of cells.
example, the GISSI-Prevenzione trial reported a 45% reduction
in sudden death in post-MI patients treated with omega-3 PUFA
supplements (Marchioli et al., 2002). However, recent clinical
trials for the secondary prevention of adverse cardiovascular
events following myocardial infarction such as the OMEGA and
Alpha-Omega trial have not replicated the earlier success seen
in the GISSI-Prevenzione study (Billman, 2013). In addition,
animal studies have not provided a clear consensus on the
pro- or anti-arrhythmic properties of omega-3 PUFAs (Billman,
2013). This may be attributed to differences in acute vs. chronic
administration of omega-3 PUFAs (Billman, 2013). While studies
have shown that acute application of omega-3 PUFAs reduce
several cardiac ionic currents including: Ito, INa, and IKr, the
generalizability of these results to chronic supplementation is not
clear (Xiao et al., 1995; Jude et al., 2003; Guizy et al., 2005). For
example, a recent report shows that acute application of omega-
3 PUFAs in COS7 cells increases Kv.7.1/KCNE1 (subunit which
encodes slow delayed rectifying potassium channel IKs) while
chronic application modified channel activity resulting in pro-
arrhythmic behavior (Moreno et al., 2015). In the present study,
and in the companion in vivo studies (Billman et al., 2010, 2012)
we sought to evaluate the role of chronic supplementation, and
the consequent membrane incorporation of omega-3 PUFAs, in
a canine model of SCD.
It is known that action potential prolongation in certain
settings may favor the development of triggered arrhythmias
(Rubart and Zipes, 2005). However, repolarization changes
may be pro- or anti-arrhythmic depending on the underlying
substrate (den Ruijter et al., 2007). Abnormal repolarization may
occur in individual cells or at the tissue level with resulting
increases in the propensity for SCD, which uncoupled cells
being more susceptible to arrhythmias (Rubart and Zipes, 2005).
In VF− animals, chronic omega-3 PUFA treatment resulted
in pro-arrhythmic actions, both in vivo (Billman et al., 2012)
and at the isolated myocyte level as shown in the present
publication. An interesting finding of the present study is
the discrepancy between modulation of APD and arrhythmic
potential. Although, the VF+ myocytes did show attenuation
of AP prolongation after omega-3 PUFA treatment, this was
insufficient to translate to a reduced arrhythmia potential. It is
possible that the magnitude of attenuated AP prolongation was
insufficient to protect against malignant arrhythmias induced by
acute myocardial ischemia in vivo. We used short term variability
or beat to beat variability of APD as an ex vivo parameter
to measure the instability of repolarization (Oosterhoff et al.,
2007). Increases in short term variability of repolarization has
shown to be predictive of ventricular arrhythmias in canine and
human models of disease, when repolarization is compromised
and early after depolarizations contribute to arrhythmogenesis—
as we have previously reported occurs in the VF+ model
(Oosterhoff et al., 2007; Sridhar et al., 2008). Our data suggest
that increased myocyte repolarization variability may correspond
to the previously observed pro-arrhythmic risk.
We have previously reported that chronic omega-3 PUFA
treatment in this model results in dysregulation of intracellular
calcium handling (Belevych et al., 2013), a potential contributor
to cellular arrhythmias. Collectively this suggests that at the
cellular level calcium dysregulation, rather than abnormal
repolarization in isolation, may contribute to the lack of
anti-arrhythmic efficacy of this treatment approach, while
contributing to pro-arrhythmic potential in some subjects.
Cardiac transient outward potassium current Ito is responsible
for partial repolarization during phase 1 of the cardiac action
potential (Niwa and Nerbonne, 2010). We previously reported
that a reduction in Ito alone was seen in VF− myocytes, and
therefore is insufficient to increase arrhythmia susceptibility
in this model (Sridhar et al., 2008). However, block of an
additional repolarizing current (IKr) was sufficient to induce
cellular arrhythmias in VF− myocytes (Sridhar et al., 2008).
This suggests a role for abnormal “repolarization reserve” as
part of the substrate for arrhythmias in this post-MI model.
In the present study we evaluated Ito with dietary omega-3
PUFA supplementation in a canine model of sudden death,
and there was no effect on Ito in either group. This finding
is consistent with our previous results (Sridhar et al., 2008)
and the notion that reduced Ito does not play a significant role
in altering lability of repolarization in canine models unless
other electrophysiologic parameters are altered. It is therefore
likely that other repolarizing currents are augmented by omega-
3 PUFA treatment resulting in shortened APD in the VF+
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myocytes. Verkerk et al. showed that chronic omega-3 PUFA
treatment in male pigs resulted in increased outward IK1 and
IKs, both of which would contribute to accelerated repolarization;
these currents may contribute to the accelerated repolarization
we observed in the VF+ omega-3 PUFA treated group (Verkerk
et al., 2006). Omega-3 PUFAs have been suggested to have
possible anti-fibrotic effects (Wang and O’Horo, 2011; Eclov
et al., 2015). Our data do not support an anti-fibrotic effect of
omega-3 PUFA treatment, although our post-MI model does not
result in significant right ventricular fibrosis and may limit the
ability to detect an anti-fibrotic response.
LIMITATIONS OF THE STUDY
The American Heart Association recommends 1 g of EPA+DHA
supplementation for patients with existing CHD. Identifying
dose equivalents between animals and humans remains a
challenge (Billman, 2013). The 1–4 g EPA + DHA given to
canines in the present study would be considered higher than
the normal human equivalent for individuals with existing CHD.
However, dosage used in the present study reflects previously
reported RBC and cardiac tissue levels (Billman, 2012) that are
associated with a reduction in sudden death in epidemiological
studies (Siscovick et al., 1995; Albert et al., 2002).
This study did not comprehensively evaluate ion currents
contributing to APD. Rather the integrated response to ion
currents, the action potential was used to evaluate the response
to chronic omega-3 PUFA treatment, within a rate range of 30–
120 BPM. While these rates capture the majority of the daily
heart rate range in canines, it is possible that results at higher
rates, which may occur physiologically in dogs, would have
different results. Isolated myocytes are by definition uncoupled
and therefore may have intrinsically longer repolarization and
more repolarization instability. Tissue recordings in coupled
myocardium would be required to more closely reflect the
cellular repolarization in vivo. Another consideration for
interpreting the in vivo effects of omega-3 PUFAs is the
potential for modulation of connexin activity (Baum et al., 2012;
Radosinska et al., 2013), a possibility not examined in our model.
CONCLUSION
Chronic administration of omega-3 PUFAs results in variable
electrophysiologic responses. Our previous in vivo reports in this
canine model show that such treatments may be ineffective in
VF+ animals or pro-arrhythmic in VF− animals (Sridhar et al.,
2008; Billman, 2012; Billman et al., 2012).We previously reported
that incorporated omega-3 PUFAs after chronic treatment
increased the risk of developing arrhythmias by disrupting
myocyte calcium handling (Belevych et al., 2013). Therefore,
abnormal variations in calcium regulation in VF− myocytes
could contribute to the pro-arrhythmic effects of dietary omega-
3 PUFAs in a canine model of sudden death. Abnormal calcium
handling in tandem with altered repolarization may contribute
to the observed effects of omega-3 PUFA supplementation. Our
work does not support the routine use of chronic omega-3
PUFA supplements post-MI to reduce the risk of ventricular
tachy-arrhythmias.
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